Mineralys Therapeutics Publishes Phase 2 Explore-CKD Trial Results
The Explore-CKD trial met its primary endpoint. Lorundrostat 25 mg once daily was added to an SGLT2 inhibitor; the supplied report is truncated after “ac.”
Story updates
11:08:16 AM UTC
SquawkNews
Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -- New hormonal and urinary protein data show a 41.5% reduction in serum aldosterone with additional significant…
11:08:23 AM UTC
SquawkNews
Mineralys reported Phase 2 Explore-CKD met its primary endpoint: lorundrostat 25 mg cut systolic BP by 7.5 mmHg vs placebo at 4 weeks, with 25.6% placebo-adjusted UACR and 22.1% urine protein reductions, and a 41.5% drop in serum aldosterone.Material DetailsContext by AI AnalystThis is mid-cycle va…